JP2010530218A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530218A5
JP2010530218A5 JP2010510480A JP2010510480A JP2010530218A5 JP 2010530218 A5 JP2010530218 A5 JP 2010530218A5 JP 2010510480 A JP2010510480 A JP 2010510480A JP 2010510480 A JP2010510480 A JP 2010510480A JP 2010530218 A5 JP2010530218 A5 JP 2010530218A5
Authority
JP
Japan
Prior art keywords
group
antibody
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010510480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530218A (ja
JP5989299B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/065045 external-priority patent/WO2008150841A1/en
Publication of JP2010530218A publication Critical patent/JP2010530218A/ja
Publication of JP2010530218A5 publication Critical patent/JP2010530218A5/ja
Application granted granted Critical
Publication of JP5989299B2 publication Critical patent/JP5989299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010510480A 2007-05-30 2008-05-29 リゾホスファチジン酸結合のための組成物と方法 Active JP5989299B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94096407P 2007-05-30 2007-05-30
US60/940,964 2007-05-30
PCT/US2008/065045 WO2008150841A1 (en) 2007-05-30 2008-05-29 Compositions and methods for binding lysophosphatidic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014232393A Division JP2015096507A (ja) 2007-05-30 2014-11-17 リゾホスファチジン酸結合のための組成物と方法

Publications (3)

Publication Number Publication Date
JP2010530218A JP2010530218A (ja) 2010-09-09
JP2010530218A5 true JP2010530218A5 (enExample) 2011-08-04
JP5989299B2 JP5989299B2 (ja) 2016-09-07

Family

ID=40094082

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010510480A Active JP5989299B2 (ja) 2007-05-30 2008-05-29 リゾホスファチジン酸結合のための組成物と方法
JP2014232393A Pending JP2015096507A (ja) 2007-05-30 2014-11-17 リゾホスファチジン酸結合のための組成物と方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014232393A Pending JP2015096507A (ja) 2007-05-30 2014-11-17 リゾホスファチジン酸結合のための組成物と方法

Country Status (9)

Country Link
US (3) US8158124B2 (enExample)
EP (1) EP2164992B1 (enExample)
JP (2) JP5989299B2 (enExample)
AU (1) AU2008260135A1 (enExample)
CA (1) CA2724432A1 (enExample)
DK (1) DK2164992T3 (enExample)
ES (1) ES2585702T3 (enExample)
LT (1) LT2164992T (enExample)
WO (1) WO2008150841A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US20080138334A1 (en) * 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
AU2008260135A1 (en) * 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
WO2009134776A2 (en) 2008-04-29 2009-11-05 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
US8629247B2 (en) 2009-04-14 2014-01-14 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
EP2419446A4 (en) * 2009-04-17 2013-01-23 Lpath Inc HUMANIZED ANTIBODY COMPOSITIONS AND METHOD FOR BINDING LYSOPHOSPHACIDIC ACID
US20110076269A1 (en) * 2009-06-24 2011-03-31 Pebay Alice Marie Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid
WO2011081214A1 (ja) * 2009-12-28 2011-07-07 国立大学法人東京大学 オートタキシン測定による肝線維化の検査方法および検査薬
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
US20120034631A1 (en) * 2010-06-11 2012-02-09 Wojciak Jonathan Michael Anti-lysophospholipid antibody design using antibody structures
US20120014946A1 (en) * 2010-07-14 2012-01-19 Sabbadini Roger A Prevention and treatment of pain using monoclonal antibodies and antibody fragments to lysophosphatidic acid
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2844580A1 (en) * 2011-08-09 2013-02-14 Lpath, Inc. Stem cell therapy using inhibitors of lysophosphatidic acid
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
CA2865428A1 (en) * 2012-02-29 2013-09-06 Lpath, Inc. Methods and kits for detecting and diagnosing neurotrauma
DE102012021222B4 (de) * 2012-10-27 2015-02-05 Forschungszentrum Jülich GmbH Verfahren zur Herstellung einer nanoporösen Schicht auf einem Substrat
BR112015009961B1 (pt) 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
WO2016025879A1 (en) * 2014-08-15 2016-02-18 Indiana University Research And Technology Corporation Treatment of cystic diseases
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
US9724057B2 (en) * 2015-06-30 2017-08-08 Toshiba Medical Systems Corporation Magnetic field actuation of detectors in a computed tomography scanner
JP6889432B2 (ja) * 2016-04-28 2021-06-18 学校法人甲南学園 樹脂固定ペプチド
EP3796935A4 (en) 2018-05-23 2022-03-16 The Jackson Laboratory ANTI-OX40 ANTIBODIES AND METHODS OF USE
ES2736045A1 (es) * 2018-06-21 2019-12-23 Univ Cadiz Metodos para el diagnostico y/o tratamiento de enfermedades neurodegenerativas
CN113827605B (zh) * 2021-08-27 2023-06-09 上海市肺科医院 甘油磷酸胆碱在制备预防和治疗结核病药物中的应用
EP4408468A4 (en) * 2021-09-28 2025-07-02 Frontaim Biomedicines Inc MULTIPLE FORMATS OF MOLECULAR COMPLEXES

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) * 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) * 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
PT1034298E (pt) 1997-12-05 2012-02-03 Scripps Research Inst Humanização de anticorpo murino
CA2323787A1 (en) 1998-03-13 1999-09-16 Wayne Marasco Humanized antibody and uses thereof
DE69912827T2 (de) * 1998-09-29 2004-10-21 Loke Diagnostics Aps Aarhus "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
US6248553B1 (en) 1998-10-22 2001-06-19 Atairgin Technologies, Inc. Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids
JP2002531466A (ja) * 1998-12-01 2002-09-24 プロテイン デザイン ラブス, インコーポレイテッド γ−インターフェロンに対するヒト化抗体
JP2003530081A (ja) * 1999-11-04 2003-10-14 アボット・ラボラトリーズ 改良後の自動化lpa検査法および癌検知法
US20030003479A1 (en) * 2001-04-19 2003-01-02 Millennium Pharmaceutical, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
CN102659946A (zh) * 2002-03-13 2012-09-12 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
CA2492092A1 (en) * 2002-06-28 2004-01-08 Greg Winter Immunoglobin single variant antigen-binding domains and dual-specific constructs
US7459285B2 (en) 2002-12-10 2008-12-02 Echelon Biosciences Incorporated Compounds and methods of use thereof for assaying lysophospholipase D activity
US7700792B2 (en) * 2003-12-26 2010-04-20 Ono Pharmaceutical Co., Ltd. Highly active lysophosphatidic acid and method of screening therewith
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
NZ556065A (en) * 2005-01-24 2009-04-30 Univ Texas FC-fusion constructs binding to phosphatidylserine and their therapeutic use
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US20080138334A1 (en) * 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
AU2008260135A1 (en) * 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
EP2419446A4 (en) * 2009-04-17 2013-01-23 Lpath Inc HUMANIZED ANTIBODY COMPOSITIONS AND METHOD FOR BINDING LYSOPHOSPHACIDIC ACID

Similar Documents

Publication Publication Date Title
JP2010530218A5 (enExample)
CN104903350B (zh) 特异于clec14a的新抗体及其用途
JPWO2003085399A1 (ja) 白血病、前白血病または非白血病性悪性血液疾患の判定方法及び診断薬
US11376333B2 (en) mTG substrates for covalent conjugation of compounds
RU2012136113A (ru) Ингибирование axl сигнализации в антиметастатической терапии
JP2013518055A5 (enExample)
JP2022028790A (ja) 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物
UA120027C2 (uk) Ізольоване антитіло проти собачого тимусного стромального лімфопоетину (tslp)
US20110262444A1 (en) Form-specific antibodies for nag-1 (mic-1, gdf-15), h6d and other tgf-beta subfamily and heart disease and cancer diagnoses
TW202212360A (zh) 抗cldn18.2抗體及其診斷用途
JP2009544284A5 (enExample)
WO2012042270A1 (en) Antibody specifically binding synovial microvasculature of arthritis patients
CN116888476A (zh) 成人斯蒂尔病的检查方法及检查试剂盒
JPWO2019202767A1 (ja) 抗線維化剤及び線維症のバイオマーカー
CA3058117C (en) Antibody binding specifically to n-terminal region of lysyl-trna synthetase exposed on cell membrane
JP5956424B2 (ja) 抗体、乳がんの治療に用いられる医薬組成物、腫瘍検査方法、及び、腫瘍検査用試薬
WO2018182284A1 (ko) 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
JP2008509659A5 (enExample)
US20180201660A1 (en) Anti-angiogenic vegf-ax isoform
JP6797107B2 (ja) 膵臓機能異常の検出方法及び検出用キット
US20240124564A1 (en) Anti-cleaved histone h3 monoclonal antibody that specifically recognizes neutrophil extracellular traps
JP6236665B2 (ja) 癌転移マーカー及びそれを用いた癌転移の診断方法
ES2339125T3 (es) Sp1 fosforilado como marcador en el diagnostico de esteatohepatitis no alcoholica (ehna) y diana en el cribado de farmacos para ehna.
WO2024084807A1 (ja) 線維芽細胞増殖因子18の測定方法及び測定用試薬
WO2023238869A1 (ja) 筋萎縮性側索硬化症、パーキンソン病、ハンチントン病、脊髄小脳失調症、老化に関連する変性疾患若しくは神経疾患、脳老化、あるいは脳老化を伴う疾患の予防剤又は治療剤